MOD3 Pharma — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Total funding raised: $3.2M

Overview

MOD3 Pharma is a private, pre-revenue biotech firm founded in 2018 and based in San Diego, specializing in advanced drug delivery systems. The company's platform includes precision dosing technologies, notably intranasal delivery systems, which are already being utilized by partners in Phase II clinical trials for respiratory conditions. While specific pipeline details are not publicly disclosed, its business model is centered on partnering with pharmaceutical companies to enable next-generation therapeutic administration.

Respiratory

Technology Platform

Precision drug delivery and dispensing technologies, including intranasal delivery systems for powder and liquid formulations.

Funding History

1

Total raised:$3.2M

Seed$3.2MUndisclosedNov 15, 2021

Opportunities

The growing demand for patient-friendly, precise, and non-invasive drug delivery systems, particularly for biologics and respiratory therapeutics, presents a significant opportunity.

Expansion into adjacent delivery routes (e.g., pulmonary, injectable) and new therapeutic areas could further broaden the market.

Risk Factors

Revenue is contingent on the clinical and commercial success of partners' drug candidates, creating high dependency risk.

The company also faces intense competition from large, well-capitalized drug delivery firms and must navigate complex regulatory pathways for combination products.

Competitive Landscape

MOD3 Pharma competes in the fragmented but competitive drug delivery technology sector, against large global suppliers like Aptar, West Pharmaceutical Services, and Gerresheimer, as well as numerous specialized startups. Differentiation is achieved through technical performance, ease of use, and successful clinical validation with partners.

More companies in Drug Delivery & Formulation →More companies in United States →